Clinical Significance of Toll-Like Receptor and Toll-Like Receptor Blocker
Urogenital Tract Infection · 2016
DOI: 10.14777/uti.2016.11.1.1 ↗Kurz gefasst
Fachartikel in der Zeitschrift Urogenital Tract Infection, 2016. Verfasst von Jae Young Choi und 2 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
The mammalian Toll-like receptor (TLR) family, consisting of 13 members, plays an important role in innate recognition of specific patterns of microbial products. TLR-dependent recognition subsequently causes an activation of antigen-specific adaptive immunity. TLR-mediated signaling pathways consist of two pathways that induce gene expression: the myeloid differentiation primary response gene 88 (MyD88)-dependent pathway and Toll/interleukin-1 receptor-domain containing adaptor protein-inducing interferon--dependent pathway. Synthetic TLR agonists, as well as TLR antagonists, affect and manipulate the host defense systems, and some of these immunomodulating agents may help to overcome intrinsic disturbances of the TLR system to offer new treatment options in urinary tract infection (UTI). Future studies are necessary to clarify additional associations between TLRs and severity of UTI, which may help in developing new treatment options.
Zitieren
APA
Choi, J. Y., Song, P. H., & Ko, Y. H. (2016). Clinical Significance of Toll-Like Receptor and Toll-Like Receptor Blocker. Urogenital Tract Infection. https://doi.org/10.14777/uti.2016.11.1.1
Vancouver
Choi JY, Song PH, Ko YH. Clinical Significance of Toll-Like Receptor and Toll-Like Receptor Blocker. Urogenital Tract Infection. 2016. doi:10.14777/uti.2016.11.1.1
BibTeX
@article{Choi2016,
author = {Choi, Jae Young and Song, Phil Hyun and Ko, Young Hwii},
title = {Clinical Significance of Toll-Like Receptor and Toll-Like Receptor Blocker},
journal = {Urogenital Tract Infection},
year = {2016},
doi = {10.14777/uti.2016.11.1.1}
}
EUVIMED